Replimune Group REPL Plunges After FDA Melanoma Rejection

Replimune Group Inc. stocks have been trading down by -67.12 percent amid heightened concern over trial setbacks and regulatory uncertainty.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading REPL

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

Key Takeaways Traders Need To Know

The FDA issued a Complete Response Letter (CRL) rejecting Replimune’s biologics license application for RP1 plus nivolumab in unresectable advanced cutaneous melanoma after PD‑1 failure, citing insufficient efficacy data.
The company said that without timely accelerated approval, continued development of RP1 is not viable and it will cut jobs and sharply reduce U.S. manufacturing operations.
Shares of Replimune Group dropped about 19% to roughly $4.76 on heavy volume after the CRL, before trading in REPL was halted pending further news.
A new FDA review team reversed earlier guidance that had supported a single‑arm trial and an accelerated approval path, questioning the adequacy and interpretability of Replimune’s BLA package.
Cantor Fitzgerald and Piper Sandler both downgraded REPL from Overweight to Neutral, with Piper Sandler setting a $4 price target after the regulatory setback.

Live Update At 10:02:59 EDT: On Monday, April 13, 2026 Replimune Group Inc. stock [NASDAQ: REPL] is trending down by -67.12%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

REPL has gone from a steady grinder to a full‑blown collapse on the chart. In late March, Replimune Group was trading in the $7–$8 range, closing at $8.54 on 2026/04/06. By 2026/04/10, after the FDA news, REPL finished at $4.76, a one‑day crash of roughly 19% from the prior close and more than 40% off recent highs.

The damage did not stop there. On 2026/04/13, REPL opened at $1.71 and slid to a $1.57 close. That tells traders the market is aggressively repricing Replimune Group’s future now that its lead melanoma program has been rejected. This is classic broken‑story price action.

More Breaking News

Fundamentals back up the story of a biotech still in heavy cash‑burn mode. Replimune Group posted a quarterly net loss of about $70.9M, with negative operating cash flow around $65.9M. Yet REPL still held roughly $124.7M in cash and $269.1M when you include short‑term investments, plus a strong current ratio of 5.6. For traders, that means dilution and restructuring risk are real, but an immediate cash crunch is less likely.

Why Traders Are Watching REPL After The FDA Shock

REPL just lived through the nightmare scenario every biotech trader studies. Replimune Group’s biologics license application for its oncolytic immunotherapy RP1 (vusolimogene oderparepvec) plus nivolumab in advanced melanoma was rejected via a Complete Response Letter. The FDA said the data did not convincingly show the treatment works. Even more troubling, a new review team at the agency reversed earlier feedback that had supported a single‑arm trial and an accelerated approval route.

For traders, that reversal is huge. REPL spent years building a thesis on that regulatory path. When the umpire suddenly changes the strike zone, the entire game plan breaks. That is exactly what the chart is screaming. Replimune Group dropped nearly 20% to about $4.76 on heavy volume, then trading in REPL was halted as the market waited for details. That sort of fast, violent repricing shows big money rushing for the exits.

Replimune Group then told the market that without timely accelerated approval, further RP1 development is not viable. The company plans significant job cuts and a substantial pullback in U.S. manufacturing operations, even as it points to strong response rates and durability from its IGNYTE trial. That means RP1, once the core value driver for REPL, now looks like a shrinking asset.

Wall Street is voting the same way. Cantor Fitzgerald downgraded Replimune Group from Overweight to Neutral. Piper Sandler did the same and slapped a $4 target on REPL. When multiple firms step back like this, it signals that many larger traders are likely to sit on the sidelines until a new roadmap appears.

Conclusion

Replimune Group is in full reset mode, and traders need to treat it that way. The FDA’s Complete Response Letter did more than delay RP1; it undercut the core narrative behind REPL’s lead program and forced management to admit that RP1 development is not viable without accelerated approval. Job cuts and U.S. manufacturing reductions confirm that Replimune Group is moving into capital‑preservation mode, not aggressive growth.

On the tape, that shows up as classic broken‑story trading. REPL has cratered from the $8s into the $1s in a matter of days, with a 19% plunge around $4.76 and a subsequent collapse to roughly $1.57. That kind of move often attracts day traders and short‑term swing traders looking to play dead‑cat bounces, but the primary trend remains down until price proves otherwise.

At the same time, Replimune Group still holds substantial cash and has a solid current ratio, giving it some runway to regroup. The key for traders is to respect the volatility and remember the core rule from Tim Sykes: “Cut losses quickly, without exception, and you’ll always live to trade another day.” Equally important is the process‑focused mindset emphasized by many trading educators; as Tim Bohen, lead trainer with StocksToTrade says, “The best way to learn is by tracking trades, wins, losses, and lessons learned. Every trade has something to teach.”. REPL is now a high‑risk, event‑driven name. Any future trade in Replimune Group should start with a tight plan, clear levels, diligent tracking of outcomes, and zero hesitation on exits.

This article is for educational and research purposes only and is not investment advice.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!